Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Evaxion Biotech A/S Sponsored ADR (EVAX : NSDQ)

• Company Description    Evaxion Biotech A/S is a clinical-stage biotechnology company. It involved in the development of AI-driven immunotherapies for patients with cancer and infectious diseases. Evaxion Biotech A/S is based in COPENHAGEN, Denmark. Number of Employees: 61

• Price / Volume Information    Yesterday's Closing Price: $1.86 Daily Weekly Monthly 20 Day Moving Average: 1,147,481 shares Shares Outstanding: 23.20 (millions) Market Capitalization: $43.16 (millions) Beta: -0.12 52 Week High: $10.00 52 Week Low: $1.51 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -36.95% -28.99% 12 Week -35.64% -29.25% Year To Date -57.92% -49.41%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Dr. Neergaards Vej 5F - Hoersholm,G7 2970 DNK ph: 45-5353-1850 fax: - evax-investor@evaxion-biotech.com http://www.evaxion-biotech.com

• General Corporate Information    Officers Lars Staal Wegner - Chief Executive Officer Marianne Sogaard - Chairman of the Board of Directors Jesper Nyegaard Nissen - Chief Operating Officer Niels Iversen Moller - Chief Financial Officer Lars Holtug - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29970R105 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 23.20 Most Recent Split Date: (:1) Beta: -0.12 Market Capitalization: $43.16 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.33 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.27 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.64 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -8.70% vs. Previous Quarter: 35.90% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -107.83 12/31/21 - -99.40 09/30/21 - -111.47 ROA 03/31/22 - -78.88 12/31/21 - -77.35 09/30/21 - -82.84 Current Ratio 03/31/22 - 7.55 12/31/21 - 8.03 09/30/21 - 4.16 Quick Ratio 03/31/22 - 7.55 12/31/21 - 8.03 09/30/21 - 4.16 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 1.14 12/31/21 - 1.43 09/30/21 - 0.87 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.37 12/31/21 - 0.10 09/30/21 - 0.20 Debt-to-Capital 03/31/22 - 27.19 12/31/21 - 9.11 09/30/21 - 16.90

Powered by Zacks Investment Research ©